Twice-daily delivery of nebulized formoterol fumarate was well tolerated over a 12-month treatment period in patients with moderate-to-severe chronic obstructive pulmonary disease (COPD).
Perforomist inhalation solution is the first and only FDA-approved nebulized form of Formoterol fumarate, a rapid and long-acting beta(2)-agonist.
James Donohue, chief of pulmonary medicine at the University of North Carolina at Chapel Hill, said: “The study’s findings indicate that nebulized delivery of formoterol fumarate is a safe long-term treatment option for patients with moderate-to- severe COPD who may prefer or require nebulization. Physicians should feel confident offering Perforomist inhalation solution as an additional therapeutic choice for COPD patients with moderate-to-severe disease.”
The results were included as part of the new drug application filing to the FDA for Perforomist inhalation solution.